A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts,
part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of
PCSK9 inhibitor AK102, and part 2 is double blind, randomized, placebo controlled study to
evaluate the efficacy and safety of PCSK9 inhibitor AK102. The treatment period will last 12
week.